WebMethods: This analysis included patients from 4 randomized controlled trials (RCTs) conducted by the Japan Clinical Oncology Group (JCOG): JCOG0205, JCOG0404, … Web直肠癌患者腹腔镜手术中淋巴结检出数量的相关因素研究* 2024-01-14 何华 谢嵘 党胜春 黄润生 张清 瞿建国 陈吉祥 崔磊
Prognostic relevance of primary tumor sidedness in stage II/III ...
WebThis is the first report of JCOG0205, which compared UFT/LV to standard 5-FU/levofoloinate (l-LV) in stage III CC, and the primary endpoint was DFS. 3524 Background: NSABP C-06 reported the non-inferiority of oral adjuvant uracil and tegafur plus leucovorin (UFT/LV) to weekly fluorouracil and folinate (5-FU/LV) in disease-free survival … Web20 mag 2012 · Request PDF Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III ... minimum wage rate philippines 2022
Second primary cancers and recurrence in patients after resection …
Web4053 Background: PETACC-1 trial was initiated in 1998 to investigate non-inferiority of raltitrexed (Tomudex, T) to bolus 5-FU/LV in the adjuvant treatment of stage III colon cancer. Methods: Co-primary endpoints were relapse-free survival (RFS) and overall survival (OS). The non-inferiority hypothesis required that the hazard ratio (HR) for T versus 5-FU/LV … Web7 nov 2024 · The authors are grateful to all the investigators of JCOG0205, JCOG0212 and JCOG0404 for their contribution to conducting the trials, Dr Yasuhiro Moriya as the JCOG 0205 primary investigator, Dr. Junko Eba and Dr Hiroshi Katayama in JCOG Data Center/Operations Office for design and logistics of the protocol and Ms Ayaka Nakano … Web10 mag 2024 · Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of … motamed cancer institute